Notable stock swings highlight year-end volatility as investors digest earnings, FDA news, and leadership moves
Stocks across major sectors displayed notable midday action Wednesday, with a handful of high-profile names making significant moves as markets approached the final trading day of the year.
Nike (NKE) was among the top gainers, climbing more than 2% after the company’s CEO made a strategic insider purchase of over 16,000 shares, signaling confidence in the athletic apparel giant’s outlook and bolstering investor sentiment. Nike shares have drawn attention for their resilience amid broader consumer sector pressures as investors weigh long-term growth prospects.
In stark contrast, Corcept Therapeutics experienced a dramatic sell-off, with its stock plummeting nearly 49%. The steep decline came after the U.S. Food and Drug Administration requested additional efficacy data for the company’s key drug candidate, relacorilant, dampening hopes for a smoother regulatory path despite earlier clinical promise. The setback underscores the sensitivity of biotech stocks to regulatory developments, especially late-stage clinical feedback.
Across the Pacific, Taiwan Semiconductor Manufacturing Company (TSM), a bellwether for the tech and semiconductor industry, showed steady midday movement as chip stocks continued to attract attention. TSMC, which trades on the NYSE under the ticker TSM and remains one of the largest semiconductor foundries globally, has been navigating supply chain dynamics and AI-driven demand trends this quarter. Recent data indicate mixed trading action for the stock, reflecting investor focus on both near-term earnings results and long-term industry positioning.
Elsewhere in the market, broader indices oscillated as traders balanced year-end portfolio adjustments with incoming economic signals. Other movers included Vanda Pharmaceuticals (VNDA), which surged after FDA drug approval news, and Donald Trump Media & Technology Group, which rose on announcements related to shareholder token plans.
Overall, the midday session highlighted how company-specific catalysts — from insider buys and regulatory outcomes to cyclical sector pressures — can drive significant stock performance, even as the broader market trends toward year-end stability. Investors appear to be navigating a mix of optimism and caution as 2025 draws to a close.
You might like this article:Bitcoin Ends a Turbulent Year Under Pressure
